New Zealand Approves Medicinal Use of Magic Mushrooms in Landmark Decision

New Zealand’s Ministry of Health has approved the medicinal use of psilocybin, commonly known as “magic mushrooms,” for treating mental health disorders, marking a groundbreaking shift in the country’s healthcare policy. The decision, announced on Tuesday, June 17, allows licensed psychiatrists to prescribe psilocybin-assisted therapy for patients with treatment-resistant depression, anxiety, and PTSD, following successful clinical trials.

Health Minister Dr. Ayesha Verrall cited extensive research showing psilocybin’s efficacy in reducing symptoms in patients unresponsive to conventional treatments. “This is a carefully regulated step to provide hope for those suffering from severe mental health challenges,” Verrall said. Trials conducted by the University of Auckland in 2024 demonstrated that 60% of participants with depression reported significant improvement after psilocybin therapy, compared to 20% with traditional antidepressants. The therapy involves controlled doses administered in clinical settings, combined with psychotherapy.

The decision follows Australia’s 2023 approval of psilocybin for medicinal use, positioning New Zealand as a leader in psychedelic research. However, strict regulations apply, with only trained professionals allowed to administer the drug. Public reaction has been mixed, with mental health advocates praising the move, while conservative groups warn of potential abuse.

The policy includes a $10 million fund for training therapists and establishing treatment centers. Critics argue that access may be limited to urban areas, leaving rural Māori communities underserved. New Zealand’s move could influence global attitudes toward psychedelics, with the U.S. and Canada monitoring its outcomes closely.